Literature DB >> 10389907

Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.

K Yoshikawa1, K Honda, T Inamoto, H Shinohara, A Yamauchi, K Suga, T Okuyama, T Shimada, H Kodama, S Noguchi, A F Gazdar, Y Yamaoka, R Takahashi.   

Abstract

BRCA1 is a tumor suppressor gene that is responsible for hereditary breast and ovarian cancer syndrome. To clarify the possible involvement of the BRCA1 protein in mammary carcinogenesis in sporadic and hereditary forms, we have analyzed the BRCA1 protein expression pattern in five breast epithelial cell lines, including a BRCA1-deficient cell line, and 162 breast cancer tissue samples [including 108 sporadic, 35 hereditary (BRCA1 status unknown), and 19 BRCA1-associated cases] from Japanese women. Twelve anti-BRCA1 antibodies were tested by fixation conditions, in which nuclear localization of BRCA1 protein was preserved, and by specificity of the antibodies, which was evaluated in BRCA1-deficient cancer cells. Using monoclonal antibodies applicable to immunohistochemical analysis of paraffin-embedded tissue sections, we found high-level expression of BRCA1 protein in normal mammary epithelium and various degrees of reduced expression in breast cancer cells. Of the 19 BRCA1-associated breast cancer tissues, 15 (79%) showed reduction (8 cases) or complete loss (7 cases) of nuclear expression. Thirty (28%) of 108 sporadic and 6 (17%) of 35 hereditary carcinomas showed reduced BRCA1 protein expression. Reduction of BRCA1 protein expression in sporadic carcinomas was associated with solid-tubular phenotype, with poor tubular differentiation, and with an overexpression of c-erbB-2 protein, which is one of the prognostic factors in breast cancer. Our data suggest that reduced expression of BRCA1 protein may play an important role in mammary carcinogenesis, not only in BRCA1-associated breast carcinomas, but also in sporadic carcinomas, and also suggest that mechanisms other than mutation may be involved in its reduced expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389907

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

Review 1.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

2.  BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.

Authors:  J Hilton; J Weberpals; I Lorimer; S Amin; S Islam; L Pelletier; M Daneshmand; J Hanson; M Nabavi; D Parolin; R Mallick; S Verma
Journal:  Oncol Lett       Date:  2012-04-26       Impact factor: 2.967

3.  Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.

Authors:  Michael D Tarpey; Ana P Valencia; Kathryn C Jackson; Adam J Amorese; Nicholas P Balestrieri; Randall H Renegar; Stephen J P Pratt; Terence E Ryan; Joseph M McClung; Richard M Lovering; Espen E Spangenburg
Journal:  J Physiol       Date:  2018-12-16       Impact factor: 5.182

4.  The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study.

Authors:  A Pérez-Vallés; M Martorell-Cebollada; E Nogueira-Vázquez; J A García-García; E Fuster-Diana
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

5.  RAD51 variant proteins from human lung and kidney tumors exhibit DNA strand exchange defects.

Authors:  Michelle C Silva; Milagros D Morrical; Katie E Bryan; April M Averill; Julie Dragon; Jeffrey P Bond; Scott W Morrical
Journal:  DNA Repair (Amst)       Date:  2016-04-25

6.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

8.  Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.

Authors:  Ubaldo E Martinez-Outschoorn; Renee M Balliet; Zhao Lin; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-10-09       Impact factor: 4.534

9.  Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.

Authors:  Roy Milner; Helen Wombwell; Sonia Eckersley; Donna Barnes; Juli Warwicker; Erica Van Dorp; Rachel Rowlinson; Simon Dearden; Glen Hughes; Chris Harbron; Bob Wellings; Darren Hodgson; Chris Womack; Neil Gray; Alan Lau; Mark J O'Connor; Catherine Marsden; Alexander J Kvist
Journal:  Virchows Arch       Date:  2013-01-25       Impact factor: 4.064

Review 10.  Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery.

Authors:  Michael P Lisanti; Ubaldo E Martinez-Outschoorn; Federica Sotgia
Journal:  Cell Cycle       Date:  2013-07-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.